Clinical Trials for Celltech

Explore 22 clinical trials worldwide

Showing 1-22 of 22 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Celltech

Clinical Trials (22)

NCT07052383
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
PHASE1Not yet recruiting
15 participants
Started: Aug 20, 2025 · Completed: Oct 10, 2027
2 conditions2 sponsors1 location
NCT07077252
Phase I/II Study of SCTB39G in Advanced Solid Tumours
PHASE1/PHASE2Not yet recruiting
30 participants
Started: Jul 28, 2025 · Completed: Oct 17, 2027
1 condition1 sponsor1 location
NCT07040072
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
PHASE1Not yet recruiting
10 participants
Started: Jun 30, 2025 · Completed: Jun 30, 2028
1 condition3 sponsors1 location
NCT07050641
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
PHASE1/PHASE2Recruiting
110 participants
Started: Jun 23, 2025 · Completed: Jun 30, 2028
1 condition1 sponsor1 location
NCT06790888
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
NANot yet recruiting
78 participants
Started: Feb 28, 2025 · Completed: Dec 31, 2027
1 condition2 sponsors0 locations
NCT06841042
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
PHASE1/PHASE2Recruiting
168 participants
Started: Feb 28, 2025 · Completed: Oct 31, 2028
1 condition1 sponsor14 locations
NCT06769984
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
PHASE1/PHASE2Not yet recruiting
100 participants
Started: Feb 19, 2025 · Completed: Sep 19, 2028
1 condition1 sponsor0 locations
NCT06801509
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
PHASE1/PHASE2Not yet recruiting
540 participants
Started: Feb 15, 2025 · Completed: Oct 10, 2027
1 condition1 sponsor1 location
NCT06754605
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
PHASE1/PHASE2Recruiting
480 participants
Started: Feb 6, 2025 · Completed: Jul 30, 2027
1 condition1 sponsor2 locations
NCT06774664
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
PHASE1/PHASE2Not yet recruiting
99 participants
Started: Jan 31, 2025 · Completed: Mar 31, 2029
1 condition1 sponsor20 locations
NCT06672536
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
PHASE1/PHASE2Recruiting
82 participants
Started: Nov 26, 2024 · Completed: Jan 11, 2027
1 condition2 sponsors1 location
NCT06600022
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
PHASE1/PHASE2Recruiting
441 participants
Started: Oct 10, 2024 · Completed: Apr 30, 2028
1 condition1 sponsor1 location
NCT06482905
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
PHASE1Recruiting
52 participants
Started: Sep 4, 2024 · Completed: Jun 30, 2027
2 conditions3 sponsors4 locations
NCT06197009
Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
PHASE2Not yet recruiting
168 participants
Started: Jul 1, 2024 · Completed: Aug 1, 2026
1 condition1 sponsor1 location
NCT06318884
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
PHASE1Not yet recruiting
76 participants
Started: Apr 30, 2024 · Completed: Dec 31, 2027
1 condition1 sponsor3 locations
NCT06304818
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
PHASE1/PHASE2Not yet recruiting
515 participants
Started: Apr 30, 2024 · Completed: Dec 30, 2028
1 condition1 sponsor0 locations
NCT06252298
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
PHASE1Recruiting
74 participants
Started: Feb 28, 2024 · Completed: Feb 28, 2027
1 condition1 sponsor1 location
NCT05888870
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
PHASE4Recruiting
50 participants
Started: Nov 22, 2023 · Completed: Dec 1, 2026
1 condition2 sponsors1 location
NCT06041061
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
PHASE3Active, not recruiting
18,000 participants
Started: Aug 13, 2023 · Completed: Aug 31, 2028
2 conditions6 sponsors5 locations
NCT05308576
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
PHASE3Active, not recruiting
10,000 participants
Started: Dec 26, 2022 · Completed: Apr 30, 2024
2 conditions1 sponsor1 location
NCT04709328
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
PHASE2/PHASE3Not yet recruiting
690 participants
Started: Mar 28, 2021 · Completed: Mar 1, 2022
2 conditions1 sponsor0 locations
NCT04560894
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
PHASE2/PHASE3Active, not recruiting
405 participants
Started: Nov 11, 2020 · Completed: Sep 30, 2024
1 condition1 sponsor1 location